Mankind Pharma Limited has submitted a regulatory disclosure under Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, intimating its participation in investor conferences.
The company officials will participate in the 2026 Jefferies Global Healthcare Conference scheduled from November 16, 2026, to November 19, 2026, in London. The meeting format will include both one-on-one and group meetings with investors and analysts.
The company specifically states that during these meetings, no unpublished price sensitive information (UPSI) shall be disclosed. All discussions will be based on information already available in the public domain and the general business outlook of the company.
The disclosure notes that the schedule is subject to change due to exigencies on either side. The intimation has been uploaded to the company's website at www.mankindpharma.com.